Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Self-Help Booklets for Sleep in Adults With Pulmonary Hypertension

4 agosto 2026 aggiornato da: University of Sheffield

Development and Pilot Randomised Controlled Trial of a Self-help Sleep Hygiene Intervention to Help Individuals With Pulmonary Hypertension

The researchers have developed a set of self-help booklets for adults with pulmonary hypertension (PH) who are experiencing sleep problems. The booklets include sleep hygiene advice and are based on a psychological treatment called Cognitive Behavioural Therapy for Insomnia (CBT-I).

CBT-I is a structured, evidence-based treatment for ongoing sleep problems. It helps people understand how their thoughts, behaviours, and daily routines can affect their sleep. It aims to improve sleep quality and help people fall asleep more easily and get back to sleep if they wake during the night.

CBT-I is one of the most effective treatments for ongoing sleep problems. The self-help programme consists of four booklets, which participants will work through at home over four weeks, completing one booklet each week in their own time. The aim of the study is to find out whether the self-help booklets improve sleep quality in people with pulmonary hypertension.

Participants will be asked to complete questionnaires about their sleep and mental wellbeing, including symptoms of anxiety and depression. Participants will then be randomly allocated to one of two groups. The intervention group will receive the self-help booklets during the study. The wait-list group will receive the booklets at a later date if they are found to be helpful. Having two groups allows the researchers to compare the results and determine whether any improvements in sleep are due to the self-help booklets.

Participants in the intervention group will also be contacted during the programme to ask about their experiences of using the booklets. Both groups will complete the questionnaires again after four weeks and then again one month later. Participants in the intervention group will also be contacted at the end of the study to discuss their experiences of taking part.

Panoramica dello studio

Stato

Non ancora reclutamento

Descrizione dettagliata

Pulmonary hypertension (PH) is an umbrella term used to describe conditions associated with elevated blood pressure in the pulmonary arteries. Approximately 8,000 people live with PH in the UK severe enough to need specialist care. Without this, the disease can lead to right sided heart failure and early mortality. The range of symptoms include breathlessness, fatigue and chest pain and many have to deal with the high burden of treatment and reduced physical activity.

As treatments PH have advanced, survival rates have improved, drawing attention to the burden the disease places on both healthcare systems and individuals. However, despite increased longevity, symptoms remain significant, and most forms of PH are still incurable. Improving health-related quality of life (HRQoL) is therefore a key priority.

Whilst the research exploring sleep and PH is limited, the prevalence and impact that sleep disturbances can have on HRQoL and the ability to cope with symptoms is becoming more recognised. Research has found an association between increasing levels of sleep disturbances and a worsening of PH symptoms, HRQoL and psychological states. This suggests that psychological distress could be one factor explaining sleep disturbances, or at least is a consequence of sleep difficulties. Further research is needed to identify the relationship between sleep disturbances and psychosocial distress, and to test interventions that target sleep. While there is a growing number of trials exploring the usefulness of psychological therapies targeting distress associated with PH, none have specifically examined the impact on sleep.

Currently there are no National Healthcare Service (NHS) commissioned sleep pathways specifically for individuals with PH and no PH specific sleep interventions are recommended by the National Institute for Health and Care Excellent (NICE). Individuals would receive non-disease specific interventions and this is likely to pose a barrier to accessing care. NICE guidelines recommend advice (self-help) about sleep hygiene as a usual treatment, with face-to-face CBT-I recommended as best practice if insomnia symptoms persist.

The primary aim of this study is to develop a self-help sleep hygiene intervention specifically tailored for individuals who have been diagnosed with PH, in order to improve their self-reported sleep quality. This intervention will be created in collaboration with PHA UK, so that both experts by education and experts by experience can contribute to its structure and content. PHA UK, is the leading charity in the UK for people impacted by PH with over 4,500 service users.

The secondary aim of the study is to conduct a pilot randomised controlled trial to explore the acceptability and feasibility of this tailored intervention, through the collection of both quantitative and qualitative data. This will focus on: recruitment; adherence; retention; outcome measure data; participant feedback and any adverse effects and will guide decisions on the feasibility of progressing to a full RCT.

Participants will be into one of two groups at random. One group will receive the self-help intervention within a few days. The other group will receive the intervention once the study is complete, but only if the intervention was found to be helpful. Participants in the intervention group, will be asked to work through the intervention in their own time at home. The intervention includes information about pulmonary hypertension and sleep and how the two can interact. It will also provide them with range of techniques and skills to practice, to help them to get a better night sleep and reduce the worry, low mood and physical symptoms associated with poor sleep and insomnia.

All participants will be required to complete series of measures before and after the intervention and at a one month follow up. This study is a 2 (intervention or control group) x 3 (pre, post, 1-month follow up) mixed factorial design. Due to the nature of the intervention, this study will not involve any blinding of participants to group allocation.

Quantitative Data:

  • As a pilot study, the primary aim is to explore the feasibility and potential effects of the intervention to inform a definitive trial, rather than to definitively test hypotheses.
  • Descriptive statistics of demographic variables and baseline measures will be provided for each group to show comparability and indicate effectiveness of randomisation.
  • To explore the preliminary effectiveness of the intervention a mixed ANOVA will be conducted to examine between subject factors (intervention vs control) as well as within subject factors (pre, post, one-month follow up) and will determine whether changes in sleep quality over time differ between the two groups.
  • Statistical significance will be set at α = .05 for all statistical analysis.
  • In addition to testing for statistical significance, effect sizes will be calculated using Cohen's d and may guide power analysis for a future trial.
  • Both intention-to-treat and per-protocol analyses may be explored to assess the consistency of results. Findings may inform the design and methodology of a full RCT in the future.
  • Descriptive statistics for attrition rates will be reported and baseline characteristics between those who dropped out vs those who completed the study will be compared to identify possible causes of attrition and issues with acceptability. Chi square tests will be used to compare categorical variables and t-tests used for continuous variables.
  • All analysis will be conducted using IBM SPSS Statistics.
  • Descriptive statistics of participant feedback will be reported.

Qualitative Data:

The data gathered from the feedback questionnaires will be analysed using content analysis:

  • The objective of the analysis is to explore the acceptability of the intervention.
  • A coding scheme will be developed, including categories relevant to the objective.
  • Responses will be coded and then categorised.
  • The data will be analysed to explore any patterns or trends that arise.
  • Conclusions will be drawn and these will be coherently reported.

Tipo di studio

Interventistico

Iscrizione (Stimato)

60

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

  • Nome: Isaac Bhatoy, Trainee Clinical Psychologist
  • Numero di telefono: (+44) 114 222 6533
  • Email: ibhatoy1@sheffield.ac.uk

Backup dei contatti dello studio

Luoghi di studio

    • South Yorkshire
      • Sheffield, South Yorkshire, Regno Unito, S1 4DP
        • Clinical Psychology Unit
        • Sub-investigatore:
          • Nigel Beail, Prof
        • Sub-investigatore:
          • Andrew Thompson, Prof
        • Sub-investigatore:
          • Iain Armstrong, Dr
        • Contatto:
        • Contatto:
        • Investigatore principale:
          • Isaac Bhatoy, Trainee Clinical Psychologist

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

Participants much be aged 18 years and over.

Must have a diagnosis of PH, which they will be asked to self-report i.e. we will not ask for proof.

Must be able to meet the requirements of the study: give informed consent; complete questionnaires; be literate in English.

Must self-report sleep difficulties. This will be asked as a categorical (yes/no) question rather than captured through an outcome measure. No sleep measure has been validated for this population. Whilst we can measure sleep, we are unable to quantify difficulties and cannot use a more standardised method of determining a clinical cut off for when a participant may be included or excluded from the study.

Exclusion Criteria:

Participants displaying any significant issues of risk such as self-reported thoughts of harm to self or suicidal thoughts will not be eligible for this study. This is because they are unlikely to benefit from a self-help intervention. this will be asked during a screening questionnaire prior to accessing the consent form. Instead, we will signpost this group to relevant services.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Altro
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Nessun intervento: Wait List Control Group
Participants in the wait-list control group will not receive the self-help intervention during the study and will be compared with the intervention group on the study outcome measures. If the self-help intervention is found to be helpful, participants in the wait-list control group will be offered the intervention after the study has been completed.
Sperimentale: Intervention Group
The intervention will be a series of self-help booklets aiming to improve sleep quality. The content and length of the intervention has been finalised in collaboration with PHA-UK to ensure it is also informed by experts by experience and education and the Medical Research Council framework for developing complex interventions (Skivington et al., 2021) will be adhered to.

Participants randomised to the intervention group will be sent a sleep hygiene self-help intervention for PH. The content of the sessions has been informed by pre-existing self-help booklets, sleep hygiene advice and CBT-I interventions and has been created in collaboration with PHA-UK.

The self-help materials will be provided online and will take 4 weeks for the participant to complete at home, with one booklet for each week:

WEEK ONE: Sleep difficulties and PH WEEK TWO: How to sleep better WEEK THREE: Working on tricky thoughts WEEK FOUR: Maintaining progress

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pittsburgh Sleep Quality Index (PSQI)
Lasso di tempo: Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
Consists of 19 items that generate seven component scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Each component is scored from 0 to 3, with higher scores indicating greater dysfunction; these are summed to yield a global score ranging from 0 to 21.
Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Sleep Hygiene Index (SHI)
Lasso di tempo: Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
Consists of 13 items that measure the frequency of behaviours such as consumption of caffeine or alcohol before bedtime, irregular sleep schedules, and engaging in stimulating activities prior to sleep. Respondents rate each item on a five-point Likert scale ranging from 0 (never) to 4 (always), with higher scores indicating poorer sleep hygiene.
Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
Generalized Anxiety Disorder 7 (GAD-7)
Lasso di tempo: Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
Assess symptoms of generalized anxiety over the past two weeks. Each of the seven items corresponds to core anxiety symptoms and is rated on a 4-point Likert scale from 0 ("not at all") to 3 ("nearly every day"), yielding a total score ranging from 0 to 21. Scores of 5, 10, and 15 represent cut-off points for mild, moderate, and severe anxiety and it has a reliable change index of 4.
Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
The Patient Health Questionnaire-8 (PHQ-8)
Lasso di tempo: Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
It contains eight items, each scored from 0 ("not at all") to 3 ("nearly every day"), generating a total score ranging from 0 to 24. Clinical cut-offs of 5, 10, 15, and 20 correspond to mild, moderate, moderately severe, and severe depression, respectively. Scores below 10 suggest mild symptoms or no significant depression.
Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
emPHasis-10
Lasso di tempo: Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
Assess HRQoL in individuals with PH It contains 10 items covering key domains relevant to the lived experience of PH, including breathlessness, fatigue, emotional wellbeing, and social functioning. Each item is rated on a 0-5 Likert scale, with total scores ranging from 0 to 50. Higher scores indicate a lower HRQoL.
Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
Dyspnoea-12 (D12)
Lasso di tempo: Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).
Assesses the severity and impact of breathlessness, which is a common symptom of PH. The D12 is a validated, 12-item measure that captures both physical and affective components of dyspnoea, with total scores ranging from 0 to 36; higher scores indicate greater symptom burden.
Outcome measures will be collected before the intervention (baseline), immediately after the four-week intervention, and at a one-month follow-up (eight weeks from baseline).

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Pubblicazioni generali

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 settembre 2026

Completamento primario (Stimato)

1 marzo 2027

Completamento dello studio (Stimato)

1 marzo 2027

Date di iscrizione allo studio

Primo inviato

27 luglio 2026

Primo inviato che soddisfa i criteri di controllo qualità

4 agosto 2026

Primo Inserito (Effettivo)

10 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

10 agosto 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

4 agosto 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

The participants data will not be shared with any researchers outside of the research team and all participants data will be anonymised in any future publications.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi